Know the world your program runs in.

Tenet reads where the people who need a therapy are, how they live, and what stands between them and care. Then it turns that into decisions, at every stage of a drug's life.

Tenet reads the world around a program and turns it into decisions at every stage of a drug's life.

What Tenet knows.

Where the people who need a therapy actually are.
How they live, and how they reach care.
What stands in the way, and what has changed since the plan was made.

Answered at neighborhood grain for every place a program touches, and delivered however your team works: on a screen, in a report, or straight into your own systems. The screens are the implementation. The intelligence is the product.

One read, every decision in a drug's life.

The same intelligence that shapes a protocol shapes where it runs, how it is monitored, how approvals hold, and where the therapy reaches people afterward.

Designing the program

Does this population fit this protocol?

Who has the condition, where they are, and what the protocol asks of them.

Choosing where it runs

Which places, in what order.

The same read at site grain, with a forecast and a score attached.

While it runs

Does the plan still hold?

Continuous, because the world that justified the plan keeps moving.

After approval

Where do the follow-on studies go?

They have to reach the same people, in the same places.

Reaching patients

Where does this therapy need to be?

The same population read, as a commercial and access decision.

Measured against what actually happened.

9%
Fewer errors predicting whether a trial stops early.
21%
Fewer errors predicting enrollment pace.
1.15B
Data points, ingested continuously.

Born out of more than a hundred years of family expertise in clinical research.

Tenet is the judgement experienced operators carry in their heads, made on every place a program touches, every day, and scored.

Every question it answers comes back to one: where are the people who need this, and how do they live? Answer that well and trials finish, programs hold, and therapies reach the people they were made for. That is what health access looks like in practice.

Four people.

Hunter WaltonChief Executive OfficerJD. The vision, and the intelligence.
Camron JonesChief Technology OfficerThe platform. Boeing Defense.
Greg JonesChief Operating OfficerMBA. Operations. Medical device.
John ArthurChief Strategy OfficerJD. Strategy, partners, and everything external.

If you decide where a program goes, or how it reaches people, we would like to talk.

We start by reading your program's footprint on public data, before anything is shared. You see what we see. From there, a ninety-day Proof of Signal on one live program.

info@usetenet.ai